Abstract
In long-term treatments or in treatments associated with frequent severe adverse events (AEs) such as those for oncology, it is important to know the probability of occurrence of AEs over time and their severity. However, some patients discontinue treatment and drop out of the clinical trial. Assumption that the drop-outs are non-informative is not always true and are not validated by data. We propose a method of applying competing risk analysis by defining events of 'occurrence of AE' and 'drop-out prior to AE'. We focus on one AE at a time. We distinguish obvious non-informative censoring from other censorings that may not be non-informative. Therefore, our approach does not need an independent assumption for drop-outs. The cumulative incidence function estimator (CIFE) for the AE by severity can be obtained by treating the degree of severity as a competing risk within the AE. We also propose a non-parametric estimator of CIF for sequential occurrence of the same AE by forming a subset of subjects with prior occurrence(s) of the same AE and by applying Wang and Wells' estimator. We give a very simple formulation of the cumulative joint incidence function estimator (CJIFE) for subjects who drop out of the clinical trial after having suffered from the AE at least one time. We evaluate the performance of Pepe's variance estimator for CJIFE with small samples by simulations. We find that it works well with a sample size more than 100. A useful graphical presentation for CIFEs and CJIFE is shown.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.